Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal ...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...

The global smart syringes market is poised for substantial growth, projected to escalate from a valuation of US$ 10.22 billion in 2024 to US$ 24.37 billion by 2033, reflecting an impressive CAGR of 10 ...

Post the infusion, core liquidity, taking into account banking system liquidity along with government cash balances, will remain in a "comfortable surplus" of 1.6 trillion rupees by March-end from ...

Canada Objective To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with ...

This mythbuster has been updated to include further information on glucagon, including storage of a GlucaGen HypoKit. This box only lists significant updates, for example where we are updating the ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With the potential to significantly change consumer eating habits, they are ...

Zepbound comes as a solution in a single-dose prefilled pen or in a single-dose vial for use with a syringe and needle. (The syringe and needle aren’t provided with this form of Zepbound.) ...

(Bergman et al., 1981; Caumo and Luzi, 2004). Another method for studying glucose-insulin-glucagon dynamics is the isoglycemic intravenous glucose infusion (IIGI), which matches the glucose excursion ...

Background: Previous findings on using Glucagon-like peptide-1 receptor agonist (GLP1-RA) as an antidepressant were conflicting, lacking large-scale studies. We used population-based data to ...